Non-Small Cell Lung Cancer (NSCLC)

>

Latest News

The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.
Elironrasib Earns FDA Breakthrough Designation for KRAS G12C-Mutant NSCLC

July 24th 2025

The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.
DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

July 23rd 2025

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.
Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC

July 22nd 2025

Particularly strong efficacy signals were observed in patients with non-squamous non–small cell lung cancer previously treated with PD-1 inhibition.
Nadunolimab Combo Exhibits Early Efficacy in Advanced NSCLC

July 17th 2025

The Oncomine Dx Express Test may generate results in as little as 24 hours when used on the Ion Torrent Genexus Dx Integrated Sequencer.
FDA OKs NGS Test for Tumor Profiling and as CDx for Sunvozertinib in NSCLC

July 7th 2025

Latest CME Events & Activities

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and AD...

September 6, 2025

Register Now!

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Register Now!

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

View More

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

View More

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

View More

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

View More

More News